OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Tokenizing loops of antibodies	267
Correction	179
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	175
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	160
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	153
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	141
Optimization strategies for monoclonal antibody production: advances in simulation and artificial intelligence in bioprocessing	102
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	102
Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies	97
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	92
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	91
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	90
An antibody developability triaging pipeline exploiting protein language models	78
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	72
Correction	67
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization	65
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	59
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	58
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	57
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	56
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	55
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	51
Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry	48
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	47
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	46

A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	42
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	42
Impact of IgG subclass on monoclonal antibody developability	41
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	40
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	39
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	38
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	38
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates	38
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	37
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	36
Antibodies to watch in 2024	36
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	36
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	35
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions	34
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	34
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	33
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	33
Discovery of broadly neutralizing V _H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	33
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO	33
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	31
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG ₁ antibody	29
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	29
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	29
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	29
Quantifying antibody binding: techniques and therapeutic implications	29
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	28
Correction	28
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	28
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	27
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	27
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	26
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	26
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	26
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	26
Antibodies to watch in 2026	25
Evolution of phage display libraries for therapeutic antibody discovery	25
Cost and supply considerations for antibody therapeutics	25
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	23
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	23
Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning	23
A glyco-engineering approach for site-specific conjugation to Fab glycans	23
Electrostatic properties of human germlines and biodistribution of small biologics	23
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	22
Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis	22
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	22
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	22
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	22
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	21
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	21
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors	21

Leveraging multi-modal feature learning for predictions of antibody viscosity	21
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	21
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	21
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	21
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	20
Predicting antibody self-association with sequence–structure fusion models: the central role of CSI-BLI in early developability screening	20
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	20
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	19
Reduction of monoclonal antibody viscosity using interpretable machine learning	19
Structural and biochemical differences between non-catalytic and catalytic antibodies	19
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	18
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	18
Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle ^TM variants	18
Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper	18
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	18
Predicting purification process fit of monoclonal antibodies using machine learning	17
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	17
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	16
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	16
Multidimensional maturation of antibody variable domains with machine-learning assistance	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	15
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	15
Structure–function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody	15
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	15
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	15
Physics-based surface patch analysis for prediction of hydrophobic contribution to viscosity of mAbs	15
Alpseq : an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing	15
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	15
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies	14
Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy	14
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	14
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	14
Correction	14
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	14
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	14
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	14
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	14
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	14
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	14
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	14
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	14
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	14